Key result
LMWHs or heparinoids after acute ischaemic stroke reduced deep vein thrombosis compared with UFH (OR 0.55; 95% CI 0.44-0.70), with no significant difference in all-cause death (OR 1.06).
Why the study?
Do low-molecular-weight heparins or heparinoids reduce death or dependency compared with standard unfractionated heparin in patients with acute ischaemic stroke?
Systematic Review (n=3,137)
Do low-molecular-weight heparins or heparinoids reduce death or dependency compared with standard unfractionated heparin in patients with acute ischaemic stroke?
In patients with acute ischaemic stroke, LMWHs or heparinoids reduce DVT compared to UFH, but evidence is insufficient to determine effects on functional outcomes, death, or major bleeding.
No takes yet. Share an insight, caveat, or question.
LMWHs or heparinoids may be preferred for DVT prophylaxis after ischaemic stroke; extends safety data on mortality but leaves effects on dependency open.
Sandercock et al. (2017) conducted a systematic review in acute ischaemic stroke (n=3,137). Low-molecular-weight heparins or heparinoids vs. standard unfractionated heparin (UFH) was evaluated on Proportion of people who are dead or dependent for activities in daily living. LMWHs or heparinoids after acute ischaemic stroke reduced deep vein thrombosis compared with UFH (OR 0.55; 95% CI 0.44-0.70), with no significant difference in all-cause death (OR 1.06).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: